(Total Views: 238)
Posted On: 03/03/2022 9:22:21 AM
Post# of 25719
$STAB CORRECTION - Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19
Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19)
FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Statera Biopharma, Inc. (Nasdaq: STAB), please note an additional sentence has been added to the fifth paragraph. The corrected release follows:
https://finance.yahoo.com/news/correction-sta...00840.html
Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19)
FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Statera Biopharma, Inc. (Nasdaq: STAB), please note an additional sentence has been added to the fifth paragraph. The corrected release follows:
https://finance.yahoo.com/news/correction-sta...00840.html
(0)
(0)
